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Abstract 
Schizophrenia is a common psychiatric disorder, which is characterized by severe 
distortion of reality; disturbances in thoughts, feelings and behavior; according to DSM V is a 
disorder form deviations fundamentals and characteristics of thought and perception, and by the 
innapropriate or blunted affect. The influence of genetics is believed to have a role in psychiatric 
disorders, especially if the disorder has occurred in young adults or adolescents. The 
pathophysiology of schizophrenia is closely related to disorders of the biomolecular aspects of the 
central nervous system. Dopamine activity in the striatal area and prefrontal cortex is a mechanism 
believed to be the cause of the emergence of positive and negative symptoms in schizophrenia. 
Meanwhile, neuronal cell apoptosis and increased oxidants, especially in the basal ganglia and 
prefrontal cortex areas cause worsening of negative symptoms experienced by schizophrenic 
patients. 
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Introduction 
Schizophrenia is a common psychiatric disorder, which is characterized by severe 
distortion of reality; disturbances in thoughts, feelings and behavior; according to DSM V is a 
disorder form deviations fundamentals and characteristics of thought and perception, and by the 
innapropriate or blunted affect. Schizophrenia is a psychiatric disorder that occurs in about 1% of 
the world's population. Differences in sex ratios vary depending on sample and study 
population. Age at first suffered differ between men and women, which is in late 20s - early in 
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women and teens and mid-20s in men. The influence of genetics is believed to have a role in 
psychiatric disorders, especially if the disorder has occurred in young adults or adolescents. 
Clinical symptoms of schizophrenia consist of positive symptoms (delusions, 
hallucinations, agitation, language and communication distortion, organized speech, and catatonic 
behavior), negative symptoms (blunted affect, bad rapport, passivity, apathetic, alogia, 
anhedonia, avolition , difficulty in abstract thinking , reduced spontaneity), cognitive symptoms 
(difficulties in setting goals, focusing / focusing attention, processing information, determining 
priorities, solving problems), affective symptoms (depressed mood or anxiety, feelings of guilt, 
tension, irritability), and aggressive symptoms (overhostility , self-injury, impulsivity). 1 
  
Pathophysiology of Schizophrenia 
It is believed that schizophrenia occurred in many ways. Dopamine 2 receptors are believed 
to play a role in the pathophysiology of schizophrenia. Positive symptoms result from excessive 
dopamine activity in the striatal area and mesolimbic area. While negative symptoms are 
associated with a decrease in dopamine activity in the prefrontal cortex. The use of antipsychotics 
plays a role in the action of dopamine 2 receptors because it can block dopamine receptors, so that 
the symptoms of schizophrenia can be reduced.1,2 
Apoptosis is thought to play a role in the occurrence of schizophrenia. Apoptosis is a 
programmed cell death that occurs when the cell has irreparable damage. The formation of 
oxidants or reactive oxygen species can cause cells to experience oxidative stress, then activate the 
caspase which will later cause cell apoptosis3. In addition, neuronal cell death is thought to be 
caused by an excitotoxicity process caused by excessive stimulation of the glutamate receptor 
NMDA subtype. Excessive glutamate neurotransmitters will cause overexitation of NMDA 
receptors. Then there will be excessive influx of Ca 2+ ions and cause stress on the endoplasmic 
reticulum. This is what activates the caspase and lysis cells, resulting in cell death. 4 
Dopamine also has a connection with the occurrence of neuronal cell death. Dopamine 
metabolism causes the formation of oxidants in the central nervous system. Dopamine (DA) has a 
dihydroquinone structure and in physiological conditions non-enzymatically oxidized by oxygen 
molecules and produces hydrogen peroxide (H2O2) and corresponding o-quinone . 
3,4 Non-
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enzymatic oxidation of catecholamines and PUFAs, in combination with antioxidant deficiencies 
in the brain, lead to increased lipid peroxidation, which will affect membrane fluidity, integrity 
and permeability.5 
Oxidative stress in schizophrenia 
              Oxidative stress is a condition that occurs due to an imbalance between toxic reactive 
oxygen species (ROS) and antioxidants. Each network has a difference in succeptibility to 
oxidative stress. The brain is a network that is relatively susceptible to oxidative damage because 
of its low antioxidant level, high levels of polyunsaturated fatty acids (PUFA), high mineral 
content and high oxygen demand (oxygen binding function) 1,3,5. In addition, easily oxidized 
neurotransmitters such as dopamine (DA), epinephrine and norepinephrine, are also present in the 
brain. The metabolism of neurotransmitters requires large amounts of hydrogen peroxide and 
neuronal mitochondria produce superoxide radicals (O2).5 Furthermore, the presence of toxic 
amino acids can lead to cell proteolysis. From all brain regions, basal ganglia is an area that has a 
greater risk of  free radical damage due to the highest iron content. 6,7 
Increased oxidative stress is thought to be relevant and related to the pathophysiology of 
schizophrenia, but the majority of outcomes in schizophrenic patients are very 
different. Several lipoperoxidation metabolites including malondialdehyde (MDA) and 
4hydroxynonenal (4-HNE), are thought to be the most specific and sensitive measurements of lipid 
autooksidation. The potential toxicity of free radicals can be resisted by a number of cytoprotective 
and antioxidant enzymes which reduce the amount of tissue damage. The function of the protective 
mechanism works through a cascade involving various antioxidant enzymes such as superoxide 
dismutase (SOD) and glutathione peroxidase (GPX) 5-8. 
Most measurements of oxidative stress in schizophrenic patients are carried out through 
peripheral body tissue. There is little information about oxidative processes that occur in 
cerebrospinal fluid and the brain. This may be due to peripheral oxidative damage that may 
originate from various other tissues in the body and hence, peripheral indications cannot show 
clearly the conditions or processes of oxidative stress that occur in the brain. 9 
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Red blood cells are often used to evaluate oxidative stress in patients with 
schizophrenia. Some diseases related to abnormalities of red blood cells can describe abnormalities 
in neurons, which have so far been difficult to examine in vivo. 10 Because of its accessibility, red 
blood cells are commonly used as a "window" for the central nervous system. Even so, there are 
still many shortcomings that cannot be revealed through the examination of red blood cells (Berger 
2006).  Furthermore, changes in phospholipid metabolism have been demonstrated through post-
mortem brain examination in schizophrenic patients.  Magnetic 
resonance spectroscopy provides an invivo evaluation of phospholipid metabolism in the 
brain. Using this noninvasive technique Williamson et al . have demonstrated abnormalities of 
brain phospholipid membranes in schizophrenia, but they cannot prove that these abnormalities 
are specific to schizophrenia. 10-11 
GSH, GpX and gluthatione reductase levels were significantly lower in the brains of 
schizophrenic patients compared to controls, which correlated with peripheral measurements 12-
14. In addition, there are studies of proton magnetic resonance which report a non-significant 
reduction, or even an increase in GSH concentration in the brain 14. 
There are studies that state peripheral nitric oxide (NO) metabolites can be used as markers 
of CNS changes related to NO. Total serum nitrate increases in the demyelinating disease group, 
forexample multiple sclerosis, inflammatory neurological disease and AIDS patients. 15 
Based on heterogeneous empirical evidence, there are no studies that clearly state 
peripheral biomarkers as markers of central oxidative status. Therefore, it can be concluded, the 
results of studies on CNS (cerebrospinal fluid, postmortem or experimental animals) show a slight 
correlative tendency in biomarker studies in erythrocytes, plasma or polymorphonuclear. 16 
Conclusion 
Schizophrenia is a disorder form deviations fundamentals and characteristics of thought 
and perception, and by the innappropriate or blunted  affect. The pathophysiology of schizophrenia 
is closely related to disorders of the biomolecular aspects of the central nervous system. Dopamine 
activity in the striatal area and prefrontal cortex is a mechanism believed to be the cause of the 
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emergence of positive and negative symptoms in schizophrenia. In addition, neuronal cell 
apoptosis and increased oxidants, especially in the basal ganglia and prefrontal cortex areas cause 
worsening of negative symptoms experienced by schizophrenic patients. 
GSH, GpX and gluthatione reductase levels were significantly lower in the brains of 
schizophrenic patients compared to controls, which correlated with peripheral measurements. 
Increased lipoperoxidation of metabolites including malondialdehyde (MDA) and 
4hydroxynonenal (4-HNE) in schizophrenic patients is needed to be further examined and 
approved as one of the causes of worsening clinical symptoms in schizophrenia. 
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